Confirmed improvement in Time In Range +18.4 percentage points - Reduction of time spent in hypoglycemia to only 0.9% - Diabeloop presents new real-life results of DBLG1® System

"DBLG1 System, Diabeloop’s hybrid closed-loop, improvement of Time In Range and reduction of hypoglycemic episodes allows for better diabetes management and improved quality of life.

Presented today at ATTD, the latest data from DBLG11 real-life cohort demonstrates an increase of 18.4 percentage point in Time In Range (TIR 70-180 mg/dL) on 974 patients.

This significant gain confirms the constant improvement in Time In Range, a key indicator of glucose control, in people living with Type 1 diabetes equipped with DBLG1 System since the WP72 pivotal trial (+12 points), the commercial pre-launch3 (+16.7 points) and the results of the first real-life cohort in Germany4 (+17.1 points).

With several thousand people equipped, Diabeloop’s solution continues to increase the Time In Range and thus improves the associated clinical benefits, such as better glucose control, less complications and improved quality of life.

These significant performances confirm the ability of Diabeloop’s solutions to improve glycemic control of people with T1D, in real-life, in a less controlled environment than in hospital supervised studies.

DBLG1 users in Germany, included in the real-life cohort, benefit from basic support at initialization. This demonstrates the ease of use of Diabeloop’s automated and personalized insulin delivery system and its interface..." Lire la suite